StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Outlook Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$55.64M. For fiscal 2025 it was -$67.06M. The highest annual figure on record is -$29.64M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$67.06M–
FY2024Sep 30, 2024-$71.70M–
FY2023Sep 30, 2023-$53.13M–
FY2022Sep 30, 2022-$63.07M–
FY2021Sep 30, 2021-$51.73M–
FY2020Sep 30, 2020-$36.84M–
FY2019Sep 30, 2019-$36.30M–
FY2018Sep 30, 2018-$29.64M–
FY2017Sep 30, 2017-$35.88M–
FY2016Sep 30, 2016-$51.35M–
FY2015Sep 30, 2015-$46.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$10.81M–
Q2 FY2026CQ1 2026Mar 31, 2026-$14.03M–
Q1 FY2026CQ4 2025Dec 31, 2025-$13.48M–
Q4 FY2025CQ3 2025Sep 30, 2025-$17.31M–
Q3 FY2025CQ2 2025Jun 30, 2025-$15.75M–
Q2 FY2025CQ1 2025Mar 31, 2025-$12.39M–
Q1 FY2025CQ4 2024Dec 31, 2024-$21.61M–
Q4 FY2024CQ3 2024Sep 30, 2024-$22.88M–
Q3 FY2024CQ2 2024Jun 30, 2024-$19.56M–
Q2 FY2024CQ1 2024Mar 31, 2024-$18.94M–
Q1 FY2024CQ4 2023Dec 31, 2023-$10.32M–
Q4 FY2023CQ3 2023Sep 30, 2023-$12.46M–
Q3 FY2023CQ2 2023Jun 30, 2023-$18.14M–
Q2 FY2023CQ1 2023Mar 31, 2023-$6.84M–
Q1 FY2023CQ4 2022Dec 31, 2022-$15.69M–
Q4 FY2022CQ3 2022Sep 30, 2022-$13.99M–
Q1 FY2022CQ4 2021Dec 31, 2021-$13.15M–
Q4 FY2021CQ3 2021Sep 30, 2021-$13.44M–
Q1 FY2021CQ4 2020Dec 31, 2020-$14.19M–
Q4 FY2020CQ3 2020Sep 30, 2020-$10.01M–
Q3 FY2020CQ2 2020Jun 30, 2020-$11.88M–
Q2 FY2020CQ1 2020Mar 31, 2020-$6.76M–
Q1 FY2020CQ4 2019Dec 31, 2019-$8.18M–
Q4 FY2019CQ3 2019Sep 30, 2019-$12.69M–
Q3 FY2019CQ2 2019Jun 30, 2019-$5.64M–
Q2 FY2019CQ1 2019Mar 31, 2019-$7.71M–
Q1 FY2019CQ4 2018Dec 31, 2018-$10.26M–
Q4 FY2018CQ3 2018Sep 30, 2018-$12.41M–
Q3 FY2018CQ2 2018Jun 30, 2018-$7.22M–
Q2 FY2018CQ1 2018Mar 31, 2018-$6.83M–
Q1 FY2018CQ4 2017Dec 31, 2017-$3.18M–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.91M–
Q3 FY2017CQ2 2017Jun 30, 2017-$7.34M–
Q2 FY2017CQ1 2017Mar 31, 2017-$7.84M–
Q1 FY2017CQ4 2016Dec 31, 2016-$17.80M–
Q4 FY2016CQ3 2016Sep 30, 2016-$9.95M–
Q3 FY2016CQ2 2016Jun 30, 2016-$22.03M–
Q2 FY2016CQ1 2016Mar 31, 2016-$2.95M–

More Outlook Therapeutics figures

See a number that looks wrong?